Vol 7, No 4 (2011)
Review paper
Published online: 2011-10-26

open access

Page views 962
Article views/downloads 6798
Get Citation

Connect on Social Media

Connect on Social Media

Inhibition of molecular signaling of epidermal growth factor receptor (EGFR) and its clinical potential for treating renal cell cancer

Gabriel Wcisło, Cezary Szczylik
DOI: 10.5603/ocp.v7i4.9131
Onkol. Prak. Klin 2011;7(4):197-207.

Abstract

Renal cell cancer affects circa 3% of cancer patients diagnosed with malignant disease. We have seen achievements in the treatment of renal cell cancer patients in advanced or metastatic stage for more than ten years. New therapies appeared to be a result of many experimental investigations that let us know pathophysiology of renal cell cancer at the molecular levels. Among well-defined molecular targets, EGFR (epidermal growth factor receptor) seems to have a role when its blocking could provide clinical benefits to renal cell cancer patients. Molecular signaling of EGFR is a crucial factor during development and progression in many malignant diseases. Renal cell cancer is not unveiled at the molecular levels of EGFR functions, and the same limited knowledge is the indirect result of clinical trials some EGFR inhibiting agents, already useful in medical practice of patients with colorectal cancer, head and neck malignancies or breast cancer. This paper presents a role of EGFR signaling in a renal cell cancer cell, and moreover, early results in some of more advanced clinical trials have been described as well.
Onkol. Prak. Klin. 2011; 7, 4: 197–207

Article available in PDF format

View PDF (Polish) Download PDF file